ADVERTISEMENT
Biocon's Cancer Drug Accepted For Review, Shares Hit 52-Week High
European regulator has accepted for review its breast cancer biosimilar Biocon, Mylan are exclusive partners on a broad portfolio of biosimilars Sanjeev Bhasin of IIFL has a target of Rs 1,100 on Biocon shares
26 Aug 2016, 04:33 PM IST 
Biocon and Mylan are exclusive partners on a broad portfolio of biosimilars and insulin analogs
Biocon shares jumped 5 per cent to their 52-week high on Friday after the drugmaker announced that the European regulator has accepted for review a breast cancer biosimilar jointly developed with Mylan. Biocon and American-Dutch Mylan are exclusive partners on a broad portfolio of biosimilars and insulin analogs.
"The European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Application for a proposed b...
